Cholangiocarcinoma is a relatively rare cancer, accounting for a small (~3%) percentage of all gastrointestinal malignancies. It is most often diagnosed in adults over age 50, with the most common occurrence in adults over age 70. Incidence varies by region and is higher in parts of Southeast Asia due to endemic risk factors such as liver fluke infections. In the United States and Europe, it is uncommon but has shown a gradual increase in reported incidence, particularly for intrahepatic forms. There are about 8,000 new cases of cholangiocarcinoma diagnosed in the U.S. each year.

The exact cause is often unknown, but cholangiocarcinoma is associated with chronic inflammation or injury of the bile ducts. Abnormalities within the bile ducts due to development or injury can increase risk of cholangiocarcinoma. Established risk factors include: 

1. Primary sclerosing cholangitis (PSC) - scarring and damage to the bile ducts in the liver, leading to reduced ability to filter blood and support digestion

2. Bile duct cysts of any of 3 types: choledochal cysts, biliary mucinous cystic neoplasms, intraductal papillary biliary mucinous neoplasms 

3. Hepatolithiasis (intrahepatic stones) - gall stones or biliary tree calculi

4. Chronic biliary infections - including infection with Chinese liver fluke parasite Opisthorchis and Clonorchis) common in Southeast Asia and especially Thailand, cirrhosis, chronic viral hepatitis (especially hepatitis B or C)

5. Certain inherited or inflammatory liver diseases

6. Other environmental exposures - type 2 diabetes, obesity, alcohol consumption, and cigarette smoking

7. Metabolic diseases - metabolic dysfunction-associated steatotic liver disease (MASLD) formerly nonalcoholic fatty liver disease (NAFLD)

Symptoms often appear late and depend on tumor location. Common features include:

• Jaundice (yellowing of skin and eyes), especially in extrahepatic tumors

• Dark urine and pale (white) stools due to impaired bile flow

• Pruritus (itching of the skin)

• Abdominal pain, often in the right upper quadrant

• Unintended weight loss and fatigue

• Fever or recurrent cholangitis (bile duct obstruction and infection caused by stones)

• Fatigue

• Nausea and vomiting

Intrahepatic tumors may present more subtly, sometimes with vague abdominal discomfort or incidental imaging findings.

Diagnosis typically involves a combination of clinical evaluation, laboratory testing, imaging, and tissue sampling. Because symptoms may mimic other hepatobiliary conditions, diagnosis often requires careful exclusion of benign causes of bile duct obstruction.

• Liver function tests: Often show cholestatic abnormalities (elevated bilirubin formed in the breakdown of red blood cells, elevated alkaline phosphatase protein found in the liver)

• Tumor markers: carbohydrate antigen (CA) 19-9 used to detect digestive cancers and carcinoembryonic antigen (CEA) used to detect colon cancers may be elevated but are not specific

• Ultrasound: Initial imaging to detect bile duct dilation or masses

• CT scan or MRI with MRCP (magnetic resonance cholangiopancreatography): Defines tumor location and extent

• Endoscopic procedures: ERCP or endoscopic ultrasound (EUS) for visualization, biopsy, and possible stenting

• Biopsy or cytology: Confirms diagnosis, though obtaining adequate tissue can be difficult

• Staging imaging: PET scan or additional CT/MRI to assess spread

Treatment depends on tumor location, stage, and patient health. Surgical removal is the only potentially curative treatment but is feasible only in a minority of patients diagnosed at early stages. Surgical options may include liver resection, bile duct resection, or pancreaticoduodenectomy (Whipple procedure) for distal tumors. In select cases of early perihilar disease, liver transplantation may be considered under strict protocols.

For unresectable or advanced disease:

• Chemotherapy, commonly gemcitabine-based regimens

• Targeted therapies for tumors with specific genetic alterations (e.g., FGFR2 fusions, IDH1 mutations)

• Immunotherapy in selected patients

• Radiation therapy in certain settings

Palliative interventions, such as biliary stenting to relieve obstruction and improve symptoms

The prognosis for cholangiocarcinoma is generally poor, largely because many cases are diagnosed at an advanced stage when curative treatment is not possible. Five-year survival rates are significantly higher when tumors are detected early and completely resected (about 35-45%), but overall survival remains limited for advanced disease. Outcomes vary by tumor location, stage, molecular characteristics, and response to therapy. Early detection and multidisciplinary management are critical for improving survival and quality of life.

1. Mayo Clinic - Cholangiocarcinoma (bile duct cancer)

2. Cleveland Clinic - Cholangiocarcinoma (Bile Duct Cancer)

3. NCBI - Cholangiocarcinoma

4. Mayo Clinic - Primary sclerosing cholangitis

5. https://www.cholangiocarcinoma.org/ 

6. https://www.pennmedicine.org/conditions/bile-duct-cancer 

7. Hirschfeld oncology